162 related articles for article (PubMed ID: 20580413)
21. [Optimal duration of anticoagulation of venous thromboembolism].
Savina EN; Couturaud F
J Mal Vasc; 2011 Dec; 36 Suppl 1():S28-32. PubMed ID: 22177766
[TBL] [Abstract][Full Text] [Related]
22. Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice.
Kaatz S; Fu AC; AbuDagga A; LaMori J; Bookhart BK; Damaraju CV; Tan H; Schein J; Nutescu E
Thromb Res; 2014 Oct; 134(4):807-13. PubMed ID: 25127013
[TBL] [Abstract][Full Text] [Related]
23. Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study.
Kearon C; Parpia S; Spencer FA; Schulman S; Stevens SM; Shah V; Bauer KA; Douketis JD; Lentz SR; Kessler CM; Connors JM; Ginsberg JS; Spadafora L; Julian JA
J Thromb Haemost; 2019 Jul; 17(7):1144-1152. PubMed ID: 31033194
[TBL] [Abstract][Full Text] [Related]
24. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry.
Ruíz-Giménez N; Suárez C; González R; Nieto JA; Todolí JA; Samperiz AL; Monreal M;
Thromb Haemost; 2008 Jul; 100(1):26-31. PubMed ID: 18612534
[TBL] [Abstract][Full Text] [Related]
25. Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term.
de Jong PG; Coppens M; Middeldorp S
Br J Haematol; 2012 Aug; 158(4):433-41. PubMed ID: 22734929
[TBL] [Abstract][Full Text] [Related]
26. Marburg I polymorphism of factor VII-activating protease and risk of recurrent venous thromboembolism.
Gulesserian T; Hron G; Endler G; Eichinger S; Wagner O; Kyrle PA
Thromb Haemost; 2006 Jan; 95(1):65-7. PubMed ID: 16543963
[TBL] [Abstract][Full Text] [Related]
27. The optimal duration of anticoagulation in patients with venous thromboembolism: how long is long enough?
Prandoni P; Piovella C; Spiezia L; Dalla Valle F; Pesavento R
Panminerva Med; 2012 Mar; 54(1):39-44. PubMed ID: 22278115
[TBL] [Abstract][Full Text] [Related]
28. [Current criteria to determine the duration of anticoagulant therapy].
Palareti G
Recenti Prog Med; 2007 Dec; 98(12):603-6. PubMed ID: 18369033
[TBL] [Abstract][Full Text] [Related]
29. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden.
Eichinger S; Pabinger I; Stümpflen A; Hirschl M; Bialonczyk C; Schneider B; Mannhalter C; Minar E; Lechner K; Kyrle PA
Thromb Haemost; 1997 Apr; 77(4):624-8. PubMed ID: 9134632
[TBL] [Abstract][Full Text] [Related]
30. The short- and long-term risk of venous thromboembolism in patients with acute spinal cord injury: a prospective cohort study.
Giorgi Pierfranceschi M; Donadini MP; Dentali F; Ageno W; Marazzi M; Bocchi R; Imberti D
Thromb Haemost; 2013 Jan; 109(1):34-8. PubMed ID: 23223906
[TBL] [Abstract][Full Text] [Related]
31. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
[TBL] [Abstract][Full Text] [Related]
32. Lipid lowering drugs and the risk of recurrent venous thromboembolism.
Delluc A; Tromeur C; Le Moigne E; Nowak E; Mottier D; Le Gal G; Lacut K
Thromb Res; 2012 Dec; 130(6):859-63. PubMed ID: 22939687
[TBL] [Abstract][Full Text] [Related]
33. Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study.
Cosmi B; Legnani C; Tosetto A; Pengo V; Ghirarduzzi A; Testa S; Prisco D; Poli D; Tripodi A; Palareti G; ;
Thromb Haemost; 2010 Jun; 103(6):1152-60. PubMed ID: 20352167
[TBL] [Abstract][Full Text] [Related]
34. Impact of sex and traditional cardiovascular risk factors on the risk of recurrent venous thromboembolism: results from the German MAISTHRO Registry.
Linnemann B; Zgouras D; Schindewolf M; Schwonberg J; Jarosch-Preusche M; Lindhoff-Last E
Blood Coagul Fibrinolysis; 2008 Mar; 19(2):159-65. PubMed ID: 18277138
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: A focus on fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP).
Luxembourg B; Schmitt J; Humpich M; Glowatzki M; Dressler D; Seifried E; Lindhoff-Last E
Thromb Haemost; 2009 Oct; 102(4):668-75. PubMed ID: 19806251
[TBL] [Abstract][Full Text] [Related]
36. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
37. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped.
Palareti G; Legnani C; Cosmi B; Guazzaloca G; Pancani C; Coccheri S
Thromb Haemost; 2002 Jan; 87(1):7-12. PubMed ID: 11848459
[TBL] [Abstract][Full Text] [Related]
38. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model.
Eichinger S; Heinze G; Jandeck LM; Kyrle PA
Circulation; 2010 Apr; 121(14):1630-6. PubMed ID: 20351233
[TBL] [Abstract][Full Text] [Related]
39. Apolipoprotein M and the risk of unprovoked recurrent venous thromboembolism.
Memon AA; Sundquist J; Zöller B; Wang X; Dahlbäck B; Svensson PJ; Sundquist K
Thromb Res; 2014 Mar; 133(3):322-6. PubMed ID: 24359967
[TBL] [Abstract][Full Text] [Related]
40. [Optimum duration of anticoagulant treatment after an episode of venous thromboembolism].
Couturaud F; Kearon C
Rev Pneumol Clin; 2008 Dec; 64(6):305-15. PubMed ID: 19084210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
